Abstract
In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.
Keywords:
HCV; OST; PWID; sofosbuvir; velpatasvir.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
Publication types
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Carbamates / administration & dosage
-
Carbamates / adverse effects
-
Carbamates / therapeutic use*
-
Data Interpretation, Statistical
-
Drug Administration Schedule
-
Drug Resistance, Viral
-
Drug Therapy, Combination*
-
Female
-
Genotype
-
Hepacivirus / drug effects
-
Hepacivirus / genetics
-
Hepatitis C, Chronic / blood
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / genetics
-
Hepatitis C, Chronic / virology
-
Heterocyclic Compounds, 4 or More Rings / administration & dosage
-
Heterocyclic Compounds, 4 or More Rings / adverse effects
-
Heterocyclic Compounds, 4 or More Rings / therapeutic use*
-
Humans
-
Liver Cirrhosis / drug therapy
-
Male
-
Medication Adherence
-
Middle Aged
-
Opiate Substitution Treatment*
-
Ribavirin / therapeutic use
-
Sofosbuvir / administration & dosage
-
Sofosbuvir / adverse effects
-
Sofosbuvir / therapeutic use*
-
Sustained Virologic Response
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Carbamates
-
Heterocyclic Compounds, 4 or More Rings
-
Ribavirin
-
velpatasvir
-
Sofosbuvir